Biological Evaluation of Triorganotin Derivatives as Potential Anticancer Agents
- PMID: 37175265
- PMCID: PMC10180515
- DOI: 10.3390/molecules28093856
Biological Evaluation of Triorganotin Derivatives as Potential Anticancer Agents
Abstract
Metal-derived platinum complexes are widely used to treat solid tumors. However, systemic toxicity and tumor resistance to these drugs encourage further research into similarly effective compounds. Among others, organotin compounds have been shown to inhibit cell growth and induce cell death and autophagy. Nevertheless, the impact of the ligand structure and mechanisms involved in the toxicity of organotin compounds have not been clarified. In the present study, the biological activities of commercially available bis(tributyltin) oxide and tributyltin chloride, in comparison to those of specially synthesized tributyltin trifluoroacetate (TBT-OCOCF3) and of cisplatin, were assessed using cells with different levels of tumorigenicity. The results show that tributyltins were more cytotoxic than cisplatin in all the tested cell lines. NMR revealed that this was not related to the interaction with DNA but to the inhibition of glucose uptake into the cells. Moreover, highly tumorigenic cells were less susceptible than nontumorigenic cells to the nonunique pattern of death induced by TBT-OCOCF3. Nevertheless, tumorigenic cells became sensitive when cotreated with wortmannin and TBT-OCOCF3, although no concomitant induction of autophagy by the compound was detected. Thus, TBT-OCOCF3 might be the prototype of a family of potential anticancer agents.
Keywords: anticancer agents; cell death; cytotoxicity; growth inhibition; organotin derivatives; tin; tumor cells.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures






Similar articles
-
Anticancer effects of tributyltin chloride and triphenyltin chloride in human breast cancer cell lines MCF-7 and MDA-MB-231.Tumour Biol. 2016 May;37(5):6701-8. doi: 10.1007/s13277-015-4524-6. Epub 2015 Dec 9. Tumour Biol. 2016. PMID: 26662104
-
Genotoxic Effects of Tributyltin and Triphenyltin Isothiocyanates, Cognate RXR Ligands: Comparison in Human Breast Carcinoma MCF 7 and MDA-MB-231 Cells.Int J Mol Sci. 2019 Mar 9;20(5):1198. doi: 10.3390/ijms20051198. Int J Mol Sci. 2019. PMID: 30857277 Free PMC article.
-
Tributyltin(IV) Butyrate: A Novel Epigenetic Modifier with ER Stress- and Apoptosis-Inducing Properties in Colon Cancer Cells.Molecules. 2021 Aug 19;26(16):5010. doi: 10.3390/molecules26165010. Molecules. 2021. PMID: 34443600 Free PMC article.
-
Recent Advancements in Organotin(IV) Complexes as Potential Anticancer Agents.Anticancer Agents Med Chem. 2018;18(3):335-353. doi: 10.2174/1871520617666171106125114. Anticancer Agents Med Chem. 2018. PMID: 29110624 Review.
-
Toxicity of dibutyltin, tributyltin and other organotin compounds to humans and to experimental animals.Toxicology. 1989 May 15;55(3):253-98. doi: 10.1016/0300-483x(89)90018-8. Toxicology. 1989. PMID: 2655175 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous